CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

According to Sarah Marjoram, MS, RDN, a dietitian who specializes in food as medicine, “When it comes to improving health, ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...